Co-Authors
This is a "connection" page, showing publications co-authored by Olatoyosi Odenike and Sandeep Gurbuxani.
Connection Strength
0.485
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.182
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
Score: 0.060
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.059
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.057
-
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420.
Score: 0.049
-
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
Score: 0.028
-
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
Score: 0.026
-
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
Score: 0.024